Bristol-myers Squibb Company · NYSE:BMY
Bristol-myers Squibb — 43rd Annual J.P. Morgan Healthcare Conference (January 2025)
23 slides from Bristol-myers Squibb's conference presentation, Jan 13, 2025
Slide 1: 43rd Annual J.P. Morgan Healthcare Conference
43rd Annual J.P. Morgan Healthcare Conference Christopher Boerner, Ph.D., Board Chair and Chief Executive Officer January 13th, 2025
Slide 2: Forward Looking Statements and Non-GAAP Financial Information
Forward Looking Statements and Non-GAAP Financial Information This presentation (as well as the oral statements made with respect to the information contained in this presentation) contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business deve
Slide 3: The next chapter for BMS comes into focus
The next chapter for BMS comes into focus January 2024 Today • Outlined journey to deliver sustained • Key first and/or best in class top-tier growth by end of the decade medicines driving Growth Portfolio* • Highlighted enablers: • Entering data-rich period, with – Performance of key growth brands
Slide 4: 2024 execution has strengthened our foundation
2024 execution has strengthened our foundation Advanced growth portfolio with double-digit sales growth Expanded presence in key TAs Re-established presence in neuroscience with Cobenfy Stronger Extended immuno-oncology portfolio durability with Opdivo Qvantig portfolio, Advanced late-stage
Slide 5: Overarching strategic focus: Achieve sustained top-tier growth by end of the decade
Overarching strategic focus: Achieve sustained top-tier growth by end of the decade Focusing on transformational Driving operational Strategically allocating medicines in areas where we excellence throughout capital for long-term have a competitive advantage the organization growth and returns → Del
Slide 6: Focusing on transformational medicines where we have competitive advantages
Focusing on transformational medicines where we have competitive advantages Key Ph 2/3 Key marketed products programs Investment priorities • Protein degradation Oncology/ • Cell therapy Hematology 21 • Complex biologics • Radiopharmaceuticals • Thrombosis Cardiovascular 5 • Cardiomyopathies • Heart
Slide 7: Five products key to Growth Portfolio performance
Five products key to Growth Portfolio performance • First–in-class • First-in-class • Best-in-class CD19 • First–in-class • Novel first-in-class treatment in treatment in oHCM CAR-T across the treatment, now a schizophrenia 1L MDS anemia • nHCM expansion broadest array of SoC in 1L melanoma treatmen
Slide 8: Cobenfy launch off to a strong start with the first indication for schizophrenia
Cobenfy launch off to a strong start with the first indication for schizophrenia… Cobenfy TRx Consistent customer feedback highlights 01 benefits of unique MoA across the three 800 700 TRx domains of schizophrenia 600 Cobenfy TRx performance is aligned to our 500 Christmas 02 expectations and ahead
Slide 9: …with several potential indications with multi-billion-dollar peak sales over the decade
…with several potential indications with multi-billion-dollar peak sales over the decade Ongoing registrational study readout Planned registrational study readout Alzheimer’s Alzheimer’s Disease Psychosis Disease Agitation (ADEPT-2) >6M1 people living >6M1,2 people living with AD in U.S. with AD in
Slide 10: Entering data rich period with multiple catalysts
Entering data rich period with multiple catalysts * 2025–2027 key milestones LCM pivotal data NME registrational data Key next wave early-stage data 2025 2026 2025 • Reblozyl TD MF Associated Anemia (INDEPENDENCE) • Milvexian ACS & SSP (LIBREXIA) • CD19 NEX-T Autoimmune Diseases (Breakfree-1 & 2) •
Slide 11: CELMoDs: Potential to raise efficacy bar across hematologic malignancies
CELMoDs: Potential to raise efficacy bar with highly potent protein degraders across hematologic malignacies CELMoDs offer a tailored approach of combinable regimens across patient segments2 • Potential new foundations in the multiple myeloma treatment Multiple Myeloma landscape with four ongoing pi
Slide 12: Milvexian: Potential to redefine anticoagulant therapy for thrombotic diseases
Milvexian: Potential to redefine anticoagulant therapy for thrombotic diseases Focused on addressing unmet medical need across three large indications1,2 • Combining with dual antiplatelet therapy LIBREXIA-STROKE Secondary Stroke • FXa’s not used due to excess bleeding risk ~1.3 million patients in
Slide 13: Admilparant (LPA1 antagonist): Potential to transform the treatment of pulmonary fibrosis
Admilparant (LPA1 antagonist): Potential to transform the treatment of pulmonary fibrosis ALOFT-IPF & ALOFT–PPF2: Phase 3 registrational studies following a robust Phase 2 program • IPF & PPF are fatal lung diseases with 3–5 years median U.S./EU prevalence3: survival1 Significant IPF: 233K, PPF: 485
Slide 14: Upcoming launch catalysts build upon existing portfolio and will further strengthen our growth profile
Upcoming launch catalysts build upon existing portfolio and will further strengthen our growth profile CD19 NEX-T iberdomide RYZ101 Currently marketed Auto-Immune Indications NDMM post-HSCT SCLC 1L ES (SSTR+) maintenance Growth Portfolio Growth Portfolio LCM NME NME LCM arlo-cel MM 2L+ golcadomide R
Slide 15: Continuing to drive operational excellence
Continuing to drive operational excellence Evolving our organization Increasing efficiency Improving R&D productivity • Maintaining a highly patient- • Annualized ~$1.5B in cost • Prioritizing the highest value centric approach savings to be realized by the programs end of 2025 • Greater focus on ac
Slide 16: Strategically allocating capital for long-term growth
Strategically allocating capital for long-term growth • Investing in our Growth Portfolio and R&D Investments in • Pursuing business development and partnerships innovation • R&D investment of ~$28B over the past 3 years1,2,3 • Business development investment of ~$27B over the past 3 years1,4 • Main
Slide 17: Reshaping BMS to deliver sustained top-tier growth & long term shareholder returns
Reshaping BMS to deliver sustained top-tier growth & long term shareholder returns Significantly younger, more diversified and de-risked portfolio • Focusing on which is more balanced across leading TAs transformational medicines where we have an advantage Potential 10+ NMEs & 30+ major LCM indicati
Slide 18: Bristol Myers Squibb
(h Bristol Myers Squibb’
Slide 19: Reconciliation of Certain GAAP Line Items to Certain Non-GAAP Line Items
Bristol Myers Squibb Company Reconciliation of Certain GAAP Line Items to Certain Non-GAAP Line Items For the Three Year Period Ended September 30, 2024 Three Months Ended Year Ended Year Ended Nine Months Ended Three Years Ended (Unaudited, dollars in millions) December 31, 2021 December 31, 2022 D
Slide 20: Growth Portfolio Legacy Portfolio
Growth Portfolio Legacy Portfolio Other Growth Brands1 Other Mature Brands 1. Other Growth Brands: Onureg, Inrebic, Nulojix, Empliciti, & Royalty revenues 10
Slide 21: 2024 environmental, social, and governance progress
2024 environmental, social, and governance progress Advancing patient Fostering a high-performing Reducing our ESG strategy health around the world & inclusive global workforce environment impact Named to the 2023 Dow Jones ASPIRE 10-year strategy 6 consecutive years of being SBTi validation of our
Slide 22: Clinical Development Portfolio — Phase I and II
Data as of Jan 13th, 2025 Clinical Development Portfolio — Phase I and II Phase I Phase II Anti-CCR8 Solid Tumors Krazati 1L Non-Small Cell Lung Cancer PD-L1<50% BMS-986460 Prostate Cancer Breyanzi RR Marginal Zone Lymphoma BMS-986463 Solid Tumors BMS-986482 Solid Tumors Golcadomide RR Folli
Slide 23: Clinical Development Portfolio — Phase III
Data as of Jan 13th, 2025 Clinical Development Portfolio — Phase III Phase III Registration US, EU, JP AR LDD Metastatic Castration-Resistant Prostate Cancer ROS1 NSCLC (EU) Atigotatug (Anti-Fucosyl GM1) + nivolumab 1L Extensive Stage Small Cell Lung Cancer AUGTYRO NTRK Pan-Tumor (EU, JP) 1L Non
Bristol-Myers Squibb Company — 43rd Annual J.P. Morgan Healthcare Conference (January 2025) on 6ix